SecBot SecBot
SECBOTREPLAY Home › Report › IMNM

IMNM · Cash and securities totaled $461.6M, down from $582.7M at Q1 end, with…

Immunome Inc. · 8-K filed Nov 9, 2026 at 16:05 ET

At the news

BEARISHIMPACT 5/10

8-K filed Nov 9, 2026 at 16:05 ET

Cash and securities totaled $461.6M, down from $582.7M at Q1 end, with cash runway into 2028. Key pipeline milestones include an FDA PDUFA date of April 28, 2027 for varegacestat, EMA MAA validation, and IND clearance for IM-1340.

  • Net loss of $85.8M for Q3 2026, vs $57.5M in Q3 2025
  • Cash, cash equivalents and marketable securities totaled $461.6M as of Sep 30, 2026
  • R&D expenses rose to $69.5M from $49.2M year-over-year
  • Varegacestat PDUFA target action date set for April 28, 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access